Corona vaccine update: Glenmark Provide fevipiravir for 103 per tablet
A pack of 34 tablets of FabiFlu has been priced at Rs 3,500 (Rs 103 per tablet). The dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets each day for 14 days of the treatment. However, it should only be taken after a doctor's prescription. A clinical test was conducted by Glenmark among 90 mild and 60 moderate Covid-19 patients across 11 sites in India. The drug is claimed to possess an efficacy of over 80% within the treatment of mild to moderate Covid-19 patients.
Delhi-based Brinton Pharmaceuticals, Bengaluru-based Strides Pharma, Mumbai-based Lasa Supergenerics and Hyderabad-based Optimus Pharma are a number of the opposite Indian firms that have applied for approval and are readying for its launch in India, consistent with sources.
The active pharmaceutical ingredient (API) and therefore the formulation for FabiFlu were developed by Glenmark through in-house research and development. The DCGI allowed means trials with phase III clinical trial in limited patients. The approval process is additionally under Emergency Use Authorisation (EUA).
With nearly 13,000 deaths and a deathrate of three .28%, India has nearly 4 lakh coronavirus patients as of now. On June 20, 14,516 new cases were reported within the country.
"The approval comes at a time when cases in India are spiralling like never before and putting tremendous pressure on our healthcare system. FabiFlu will reduce this pressure. Glenmark will work with the govt and medical profession to form it quickly accessible to patients across the country," said Glenn Saldanha, Chairman and director , Glenmark Pharmaceuticals.
The drug acts by stepping into cells and inhibits the activity of viral replication to scale back the viral load. Early use of antiviral drugs can control a high rate of viral replication. However, if not controlled initially, viral replication slows down in later stages leading to complications thanks to the body's violent immune reaction which can also end in organ failure, said the corporate sources.
However, experts say that it's not a 'magic drug' but can help amid rising cases. "It isn't a remedy because it isn't the sole thing we've to offer . this is often not a selected drug made for Covid-19 and has been found to be useful, but what proportion it'll be useful we'll need to see. Real efficacy are going to be known when administered on an outsized scale," said Dr Vikas Maurya, Director, Department of Pulmonology and Sleep Disorders, Fortis Hospital, Shalimar Bagh.
He added, "The neatest thing is that it's an oral drug, while Ramdesiver is an intravenous drug. It (Favipiravir) are often even taken reception . So albeit it's giving some benefit, it'll be quite useful".
A study combining two anti-viral drugs, Favipiravir (an approved drug for novel flu pandemics) with Umifenovir (an approved drug for Influenza) in Covid-19 patients is additionally being undertaken by Glenmark.
Favipiravir is already getting used commercially within the therapeutic management of COVID-19 in Bangladesh and UAE. it's sold under the name Avigan by Fujifilm Toyama Chemical and is approved in Japan since 2014 in treating influenza.
It is under the approval process in Egypt and Jordan and may be a a part of the treatment protocol in Russia, Japan and Saudi Arabia . About 18 global clinical trials in 3,000 subjects are happening including in India, USA, Canada, Italy, China, France, UK and other countries.
In Japan, the drug has been approved for compassionate use on 2,050 Covid-19 patients. it is also approved for novel or re-emerging pandemic influenza viral infection within the country. an attempt of 760 patients of Favipiravir is underway in Canada. a few of studies in China had also shown promising results. A Russian study among 390 patients had shown 80 per cent plus success rate and an attempt among 2,141 patients in Japan showed above 88 per cent success rate.
Comments
Post a Comment
thanks for your response.